Evidence map›Paper›PMID 31538327›Full record

Trial reportInternational journal of hematology2019

Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).

Koji Nagafuji, Itaru Matsumura, Takayuki Shimose, Tatsuya Kawaguchi, Junya Kuroda, Hirohisa Nakamae, Toshihiro Miyamoto, Norimitsu Kadowaki, Jun Ishikawa, Yutaka Imamura and 3 more

Abstract readClinical Trial, Phase IIMulticenter Study
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. The New ELN Recommendations for Treating CML.Journal of clinical medicine · 2020
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 1 country.

Koji NagafujiDivision of Hematology and Oncology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-machi, Kurume, 830-0011, Japan. knagafuji@med.kurume-u.ac.jp.ORCID http://orcid.org/0000-0003-4795-121X
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University, Osaka, Japan.
Takayuki ShimoseClinical Research Support Center Kyushu, Fukuoka, Japan.
Tatsuya KawaguchiDepartment of Hematology and Infectious Diseases, Kumamoto University, Kumamoto, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hirohisa NakamaeDepartment of Hematology, Osaka City University, Osaka, Japan.
Toshihiro MiyamotoDepartment of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan.
Norimitsu KadowakiDepartment of Internal Medicine, Kagawa University, Kagawa, Japan.
Jun IshikawaDepartment of Hematology and Oncology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
Yutaka ImamuraDivision of Hematology, St. Mary's Hospital, Kurume, Japan.
Hirohito YamazakiDivision of Transfusion Medicine, Kanazawa University Hospital, Kanazawa, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University, Fukuoka, Japan.
Yuzuru KanakuraDepartment of Hematology and Oncology, Osaka University, Osaka, Japan.
Kyushu University · JPKagawa University · JPKanazawa University Hospital · JPKindai University · JPKumamoto University · JPKurume University · JPKyoto Prefectural University of Medicine · JPKyushu Economic Research Center · JPOsaka City University · JPOsaka International Cancer Institute · JPSt Mary's Hospital · JPThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this multicenter phase 2 trial, Stop Nilotinib (NILSt), was to examine the safety and efficacy of discontinuation of nilotinib in patients with chronic phase (CP)-chronic myelogenous leukemia (CML). Patients with CP-CML who had achieved molecular response (MR

Indexed as

Substance Withdrawal SyndromeWithholding TreatmentAdultAgedConsolidation ChemotherapyFemaleHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedPyrimidinesRecurrenceRemission InductionImatinib MesylatenilotinibPyrimidinesCessationChronic myelogenous leukemiaDiscontinuationNilotinibTyrosine kinase inhibitor

Identifiers

PMID31538327
OpenAlexW2973478859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.